Showing results (381-390 of 653) with videos related to

Sort By:
Pageof 66
Annals of Surgical Oncology|February 18, 2011
Recurrence pattern and prognosis of pancreatic cancer after pancreatic fistulaShunji Nagai, Tsutomu Fujii, Yasuhiro Kodera, et al.
Trials|February 13, 2022
Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II studyDaisuke Hashimoto, Sohei Satoi, Hideki Ishikawa, et al.
Annals of Surgery|March 8, 2022
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01)Junpei Yamaguchi, Yukihiro Yokoyama, Tsutomu Fujii, et al.
Pancreas|May 21, 2020
Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic CancerDaishi Morimoto, Suguru Yamada, Fuminori Sonohara, et al.
BMC Sports Science, Medicine & Rehabilitation|November 9, 2016
Changes in exercise capacity, muscle strength, and health-related quality of life in esophageal cancer patients undergoing esophagectomyTakayuki Inoue, Satoru Ito, Masahiko Ando, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 26, 2012
Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registryAtsushi Nashimoto, Kohei Akazawa, Yoh Isobe, et al.
Journal of Surgical Oncology|July 1, 2014
Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancerNaoki Mashita, Suguru Yamada, Goro Nakayama, et al.
Clinical Endoscopy|July 17, 2023
Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancerKunio Kataoka, Eizaburo Ohno, Takuya Ishikawa, et al.
Surgery Today|January 29, 2020
Importance of the neoadjuvant rectal (NAR) score to the outcome of neoadjuvant chemotherapy alone for locally advanced rectal cancerToshiki Mukai, Keisuke Uehara, Toshisada Aiba, et al.
Anticancer Research|July 27, 2022
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic CancerTomohisa Otsu, Yoshikuni Inokawa, Hideki Takami, et al.
Pageof 66